Canada Markets closed

Entheon Biomedical Corp. (ENTBF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0373-0.0070 (-15.75%)
At close: 01:49PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.0443
Open0.0340
BidN/A x N/A
AskN/A x N/A
Day's Range0.0340 - 0.0373
52 Week Range0.0330 - 0.5710
Volume27,911
Avg. Volume25,982
Market Cap2.309M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.1690
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    Entheon Announces Sale of Certain DMT Clinical Assets and Filing of Provisional Novel Compound Patents

    Vancouver, British Columbia--(Newsfile Corp. - June 7, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company") today announced that it has entered into a definitive agreement (the "Agreement") dated June 7, 2022 with Cybin IRL Limited (the "Purchaser"), a subsidiary of Cybin Inc. ("Cybin"), pursuant to which the Company has agreed to sell its Phase 1 N,N-dimethyltryptamine ("DMT") study (the "DMT Study") to the Purchaser (the "Transaction") for ...

  • GlobeNewswire

    Ehave, Inc. Announces Psychedelics Precision Medicine Platform For Clinical Research

    AI-driven discovery platform enables new way to find novel pathways, as well as progress towards identifying patients who may better respond to drugs in the clinicGenetic test kit evaluates an individual's overall sensitivity and risk profile associated with psychedelic-assisted therapy MIAMI, June 01, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leading healthcare services and technology company, announced today its KetaDASH subsidiary will begin using precision med

  • Newsfile

    Entheon Biomedical Announces Non-Brokered Private Placement Financing

    Vancouver, British Columbia--(Newsfile Corp. - April 5, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, announces that it is proceeding on a non-brokered private placement financing of up to 30,000,000 Units (the "Units") at a price of CDN$0.10 per Unit for gross proceeds of up